Can a new immunotherapy combo make stomach tumors disappear before surgery?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18-75 years old, male or female; * Previously untreated, surgically resectable adenocarcinoma of the stomach or gastroesophageal junction; * Clinical stage cT3-4a/N+M0; * ECOG performance status 0-1; * Adequate function of major organs assessed within 7 days before treatment: 1. Hematological indicators (without blood transfusion within 14 days): Hemoglobin (HB) ≥90 g/L; Absolute neutrophil count (ANC) ≥1.5×10⁹/L; Platelet (PLT) ≥80×10⁹/L; 2. Biochemical indicators: Total bilirubin (TBIL) ≤1.5 × upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN; Serum creatinine (Cr) ≤1.5 × ULN or creatinine clearance (CCr) ≥60 ml/min; 3. Assessed by Doppler echocardiography: left ventricular ejection fraction (LVEF) ≥ lower limit of normal (50%); 4. Thyroid function: thyroid stimulating hormone (TSH) ≤ ULN; * Subjects of childbearing potential agree to use effective contraception during the study and for 6 months after the end of study treatment; * Subjects voluntarily participate in this study and sign written informed consent. Exclusion Criteria: * Inclusion Criteria: * Aged 18-75 years old, male or female; * Previously untreated, surgically resectable adenocarcinoma of the stomach or gastroesophageal junction; * Clinical stage cT3-4a/N+M0; * ECOG performance status 0-1; * Adequate function of major organs assessed within 7 days before treatment: 1. Hematological indicators (without blood transfusion within 14 days): Hemoglobin (HB) ≥90 g/L; Absolute neutrophil count (ANC) ≥1.5×10⁹/L; Platelet (PLT) ≥80×10⁹/L; 2. Biochemical indicators: Total bilirubin (TBIL) ≤1.5 × upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN; Serum creatinine (Cr) ≤1.5 × ULN or creatinine clearance (CCr) ≥60 ml/min; 3. Assessed by Doppler echocardiography: left ventricular ejection fraction (LVEF) ≥ lower limit of normal (50%); 4. Thyroid function: thyroid stimulating hormone (TSH) ≤ ULN; * Subjects of childbearing potential agree to use effective contraception during the study and for 6 months after the end of study treatment; * Subjects voluntarily participate in this study and sign written informed consent. Exclusion Criteria: * History of hypersensitivity to any component of QL1706, tegafur-gimeracil-oteracil potassium, oxaliplatin, docetaxel, or any of their excipients; * History of other malignant tumors within the past 5 years or concurrent other malignant tumors, except cured carcinoma in situ of cervix, non-melanoma skin cancer, and superficial bladder tumors; * Patients with distant metastasis or unresectable disease; * Prior receipt of immunotherapy (anti-PD-1, anti-PD-L1, anti-CTLA-4, etc.); * Received any anti-tumor agents within 4 weeks prior to the first study drug administration; * Patients with intestinal obstruction (including incomplete intestinal obstruction) or other gastrointestinal diseases that may lead to gastrointestinal hemorrhage, perforation or obstruction; * Patients with any bleeding event ≥ CTCAE Grade 3, unhealed wounds, ulcers or fractures within 4 weeks before screening; * Concurrent enrollment in another interventional clinical trial, except observational (non-interventional) clinical trials or follow-up phase of interventional trials; * Subjects requiring systemic treatment with corticosteroids (\>10 mg prednisone equivalent daily) or other immunosuppressants within 2 weeks before the first study drug administration; * Received live vaccines within 4 weeks prior to the first study drug administration; * Underwent major surgery or suffered trauma within 4 weeks before the first study drug administration; * Active autoimmune disease or history of autoimmune disease, except vitiligo or childhood asthma/allergy that has resolved and requires no intervention in adulthood; * History of immunodeficiency, including positive HIV test, other acquired or congenital immunodeficiency diseases, or history of organ transplantation and allogeneic bone marrow transplantation; * Subjects with inadequately controlled cardiovascular clinical symptoms or diseases; * Severe infection (CTCAE Grade \> 2) occurring within 4 weeks prior to the first study drug administration; * History of interstitial lung disease (except radiation pneumonia without corticosteroid treatment), non-infectious pneumonia, active pulmonary tuberculosis infection; patients with history of active pulmonary tuberculosis infection within 1 year before enrollment, or patients with history of active pulmonary tuberculosis infection more than 1 year ago without standardized treatment; * Pregnant or breastfeeding women; * Other concomitant diseases that, in the investigator's opinion, may seriously endanger the subject's safety or prevent the subject from completing the study.